AlphaTON Capital Unwinds 2025 Share Exchange With Compedica

The latest announcement is out from AlphaTON Capital ( (ATON) ).

On February 6, 2026, AlphaTON Capital Corp entered into an agreement with Compedica Holdings Limited to terminate and rescind their June 5, 2025 Subscription Agreement, under which AlphaTON had issued 625,000 of its ordinary shares at $8.00 per share in exchange for 1,165,501 Compedica shares at $4.29 per share. The deal fully unwinds that prior share-for-share exchange by returning each party’s securities free of encumbrances, provides mutual releases and indemnification, and is intended to restore both companies to their pre-transaction positions without additional consideration, potentially simplifying AlphaTON’s capital structure and clarifying liabilities arising from the original arrangement.

The agreement, signed and closed on the same date, includes customary representations, warranties and termination provisions, while explicitly characterizing the rescission as a business decision rather than an admission of wrongdoing. By incorporating this action into existing registration statements, AlphaTON formally records the reversal of the strategic share swap, which may affect how investors assess its exposure to Compedica and its balance-sheet composition for the period following the 2025 transaction.

The most recent analyst rating on (ATON) stock is a Hold with a $0.49 price target. To see the full list of analyst forecasts on AlphaTON Capital stock, see the ATON Stock Forecast page.

Spark’s Take on ATON Stock

According to Spark, TipRanks’ AI Analyst, ATON is a Neutral.

The score is driven primarily by weak financial performance (no revenue, persistent losses, and ongoing cash burn with signs of equity erosion). Technicals reinforce the risk with bearish trend signals (price below key moving averages and negative MACD), while valuation provides limited support due to negative earnings and no dividend yield data.

To see Spark’s full report on ATON stock, click here.

More about AlphaTON Capital

AlphaTON Capital Corp, a British Virgin Islands company formerly known as Portage Biotech, Inc., operates as a foreign private issuer with its securities registered in the U.S. The company files annual reports on Form 20-F and maintains multiple active shelf and employee share registration statements, positioning it to access capital markets and manage equity-based incentives for stakeholders.

Average Trading Volume: 6,518,774

Technical Sentiment Signal: Sell

Current Market Cap: $7.14M

For an in-depth examination of ATON stock, go to TipRanks’ Overview page.